Regeneron Pharmaceuticals, Inc. (REGN) shares plummeted 19.06 percent to $489.99, down $115.41 on Friday, after announcing mixed results from its Phase 3 trials evaluating itepekimab for chronic obstructive pulmonary disease. Regeneron is currently trading at $492.47, down sharply from its previous close of $605.39 on the Nasdaq. The stock opened at $516.00 and has traded between $492.35 and $519.78 so far today, with volume surging to 2.5 million shares. The 52-week trading range now stands at $492.35 to $1,211.20.
The AERIFY-1 trial met its primary endpoint, showing a 27 percent reduction in moderate or severe COPD exacerbations at 52 weeks in former smokers. However, the AERIFY-2 trial failed to meet the same primary endpoint, although some benefit was observed earlier in the study.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.